Our mission is to empower ophthalmology by enabling additional insights into treatment data of patients suffering from retinal eye diseases.
globally suffer from vision-threatening retinal diseases, requiring lifelong and regular treatments.
Source: WHO World Vision Report 2019
is caused by retinal diseases - and thus preventable.
Source: WHO World Vision Report 2019
is affected by Age-related Macular Degeneration (AMD), one of the leading causes of blindness
Source: WHO/Resnikoff
To optimize your IVI therapy planning, we developed the world's first AI assistant to support you with a second reading of every OCT. Our first regulated medical device software deepeye® TPS* supports planning of anti-VEGF therapy for nAMD patients.
*deepeye TPS is a CE-marked medical device
More than just data, deepeye delivers actionable insights, aiding in robust treatment planning that overcome the limitations of conventional treatment regimen like T&E, PRN, IVAN, and CATT. Our pursuit of algorithmic refinement aims to redefine the treatment narrative for retinal diseases towards a (patient) need-based "predict & treat" (P&T).
Our flexible AI platform elevates the capabilities of retinal therapy study teams, serving pharmaceutical companies, medical device manufacturers and payors with unparalleled efficiency and insight.
Human expert double reading is a proven clinical method in specialties like mammography or radiology.
In retina, a real-world study demonstrated [2a, 2b]:
3X Higher Visual Acuity
2X Higher Therapy Persistence
over 2 years at 60+ sites and 2,466 patients in a tele-ophthalmic setting (IVI Portal Münster) compared to other real-world studies like PERSEUS, OCEAN, and a US Medicare review.
Our AI assistant comes from this human expert double reading, a proven clinical method to empower every ophthalmologists with a second reading, anytime & everywhere.
2a. N. Eter et al.: “PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration”. Graefes Arch Clin Exp Ophthalmol 259 (8), 2021 Aug, pp. 2213-2223
2b. F.G. Holz et al.: “Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.”. Br J Ophthalmol.99 (2). 2015 Feb,pp. 220-226
We analyze retinal therapy datasets for new insights. Our approach focuses on partnering in commercial Phase III and IV trials for retinal therapies like anti-VEGF, complement inhibitors, corticosteroids etc. , covering retinal diseases such as nAMD, GA, DME, RVO, CSC, and PCV to help with actionable AI models to stratefy patients, drive treatment outcomes and advance retinal care.
.gif)
Based on tens of thousands of similar cases, treated with exceptional results.
Assessment of current disease activity, explained by biomarker visualization.
Prediction of expected treatment need over the coming 12 months.
Works with most OCT machines and imaging software like HEYEX2.
